Related Experiment Video
Updated: Aug 2, 2026

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
Published on: June 20, 2014
Abnormal myocardial mechanics in Kawasaki disease: rapid response to gamma-globulin
A M Moran1, J W Newburger, S P Sanders
1Department of Cardiology, Children's Hospital and the Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA. Colan@A1.TCH.harvard.edu
Insights
Kawasaki disease often causes abnormal heart contractility, but intravenous gamma-globulin rapidly improves it. Most patients recover fully, suggesting a reversible cause for the dysfunction.
Area of Science:
- Pediatric Cardiology
- Immunology
- Cardiovascular Research
Background:
- Kawasaki disease can lead to myocardial dysfunction.
- The recovery rate and time course of this dysfunction after intravenous gamma-globulin (IVIG) treatment are not well understood.
- Understanding recovery patterns may offer insights into the disease's mechanisms.
Purpose of the Study:
- To evaluate the time course and rate of recovery of myocardial contractility in children with Kawasaki disease treated with IVIG.
- To assess the relationship between clinical response and myocardial recovery.
- To explore potential mechanisms for depressed contractility based on recovery speed.
Main Methods:
- Noninvasive stress-shortening and stress-velocity analysis using echocardiograms were performed on 25 patients.
- Measurements were taken daily for 4 days during IVIG treatment (1.6-2 g/kg).
- Clinical response was defined by C-reactive protein levels and fever resolution.
Main Results:
- 56% of patients presented with depressed myocardial contractility.
- 68% showed significant improvement in contractility after IVIG, with 57% normalizing within 24 hours.
- Myocardial response strongly correlated with clinical response; all patients had normal contractility at long-term follow-up.
Conclusions:
- Depressed myocardial contractility is common in Kawasaki disease at presentation.
- IVIG therapy leads to rapid improvement in myocardial mechanics, closely mirroring the clinical response.
- The rapid recovery suggests a reversible cause, such as circulating toxins or cytokines, and indicates a good long-term prognosis.
Background:
The time course and rate of recovery of myocardial dysfunction in association with Kawasaki disease in response to intravenous gamma-globulin is unknown and may provide mechanistic clues.
Methods And Results:
The acute changes in myocardial contractility in 25 patients with Kawasaki disease were evaluated by noninvasive stress-shortening and stress-velocity analysis. Echocardiograms were performed before and then daily for 4 days during which the patients received gamma-globulin 1.6 to 2 g/kg. Before treatment, contractility was abnormally low (<2 SD) in 14 patients (56%). Contractility increased significantly (2 SD increase) in 17 (68%), including 13 of 14 with depressed contractility and 4 whose initial contractility fell within normal limits. Of the 14 patients with depressed contractility, 8 (57%) normalized within 24 hours and a further 5 (35.7%) normalized within 6 months. A clinical response to treatment (fall in C-reactive protein by 50% and/or resolution of fever within 4 days) was seen in 22 patients (88%). Contractility increased in 17 of the 22 clinical responders and was normal before therapy in the other 5. The 3 patients who did not respond clinically also had no change in contractility with gamma-globulin therapy. Long-term (more than 12 months) follow-up was available in 19 patients. All patients had normal contractility at late follow-up.
Conclusions:
More than half the patients with Kawasaki disease have abnormal contractility at presentation. Myocardial response to gamma-globulin therapy is associated with rapid improvement in myocardial mechanics, with a high concordance between the clinical and myocardial response to therapy. The speed of recovery suggests that depressed contractility in patients with Kawasaki disease is caused by a rapidly reversible process such as circulating toxins or activated cytokines. Long-term outcome is good even in those patients with slow recovery of myocardial function.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Related Concept Videos
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease III: Medical Management